Prostate Cancer clinical trials in Arizona

22 actively recruiting prostate cancer trials at 9 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed 2026-10-01

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Dendreon funds and runs this clinical trial (NCT06134232). In 2024, Dendreon reported paying the doctors leading the trial a total of $684,938 for research work on this study.

Who paid

Dendreon Pharmaceuticals LLC $684,938

Paid for research work on this trial

CHRISTOPHER PIECZONKA $53,908
LAURENCE BELKOFF $45,173
RONALD TUTRONE $44,950
PAUL SIEBER $44,200
MATTHEW TRUESDALE $40,453

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Regeneron Pharmaceuticals funds and runs this clinical trial (NCT03972657). In 2024, Regeneron Pharmaceuticals reported paying the doctors leading the trial a total of $2,249,252 for research work on this study.

Who paid

Regeneron Pharmaceuticals, Inc. $2,249,252

Paid for research work on this trial

BILAL SIDDIQUI $843,045
EDWARD GELMANN(oncologist on CancerDrs) $282,711
BENEDITO CARNEIRO FILHO(oncologist on CancerDrs) $234,450
DAVID WISE(oncologist on CancerDrs) $232,180
CHE-KAI TSAO(oncologist on CancerDrs) $172,450

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group

NCT ID: NCT06592924

Sites in Arizona:

Cancer Center at Saint Joseph's — Phoenix, Arizona